Tonix Pharmaceuticals announced positive Phase 3 RESILIENT trial results for TNX-102 SL (sublingual cyclobenzaprine HCl tablets) in managing fibromyalgia pain. The trial confirmed previous findings from the RELIEF Phase 3 trial, showing statistically significant pain reduction. Pending FDA approval (PDUFA date: August 15, 2025), TNX-102 SL could be the first new fibromyalgia drug in over 15 years.
This news is potentially transformative for fibromyalgia patients who currently face limited treatment options and often experience inadequate pain relief. The confirmation of TNX-102 SL’s efficacy in a second Phase 3 trial significantly strengthens its potential to fill this unmet medical need, offering a new non-opioid therapeutic approach. Positive clinical data demonstrating significant pain reduction and a generally well-tolerated safety profile positions TNX-102 SL as a promising alternative to current treatments, many of which come with undesirable side effects.
The RESILIENT trial involved 457 adult participants and demonstrated a statistically significant reduction in pain scores compared to placebo. All six key secondary endpoints, measuring various aspects of fibromyalgia symptoms, function, sleep disturbance, and fatigue, were also met. TNX-102 SL was generally well-tolerated, with mild, transient side effects like oral tingling/numbness and aftertaste. No serious drug-related adverse events were reported.
The upcoming FDA decision is a pivotal moment for Tonix Pharmaceuticals. A potential approval would not only validate years of research and development but also provide the company with a first-in-class treatment for a large patient population. This would represent a significant commercial opportunity and establish Tonix as a key player in the pain management market. Furthermore, positive regulatory outcomes could stimulate further research into TNX-102 SL for other conditions like Long COVID and alcohol use disorder, broadening its potential therapeutic impact. The market entry of TNX-102 SL could reshape the fibromyalgia treatment landscape, providing patients with a much-needed new therapeutic option.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
